Abstract
Inactivation of specific tumor suppressor genes by transcriptional silencing associated with hypermethylation of the promoter is a common event in cancer. We have applied the amplification of intermethylated sites (AIMS) technique to a 100 human colorectal cancers and seven cell lines to identify recurrent alterations that may unveil silenced tumor suppressor genes. Bisulfite sequencing was used to confirm differential DNA methylation results. Gene expression analysis was performed by real-time RT–PCR. An AIMS band recurrently displayed in tumors but not in normal tissues was isolated and identified as part of the CpG island of the prostacyclin synthase (PTGIS) gene promoter. PTGIS promoter was hypermethylated in 43 out of 100 colorectal cancers and in all cell lines. Bisulfite sequencing and clonal analysis confirmed the results obtained by AIMS and demonstrated biallelic hypermethylation of PTGIS promoter. Hypermethylation of the PTGIS promoter was associated with diminished gene expression, that was restored after treatment with demethylating and histone deacetylases inhibitor agents. PTGIS hypermethylation was associated with aneuploidy and p53 mutations. In the adjusted model, PTGIS methylation, but not p53 mutation, maintained the association with aneuploidy. We conclude that epigenetic inactivation of the PTGIS gene is a recurrent alteration in colorectal carcinogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Amano S, Tatsumi K, Tanabe N, Kasahara Y, Kurosu K, Takiguchi Y, Kasuya Y, Kimura S and Kuriyama T . (2004). Respirology, 9, 184–189.
Brown JR and DuBois RN . (2005). J. Clin. Oncol., 23, 2840–2855.
Cameron EE, Bachman KE, Myohanen S, Herman JG and Baylin SB . (1999). Nat. Genet., 21, 103–107.
Clark SJ, Harrison J, Paul CL and Frommer M . (1994). Nucleic Acids Res., 22, 2990–2997.
Cutler NS, Graves-Deal R, LaFleur BJ, Gao Z, Boman BM, Whitehead RH, Terry E, Morrow JD and Coffey RJ . (2003). Cancer Res., 63, 1748–1751.
Frigola J, Ribas M, Risques RA and Peinado MA . (2002). Nucleic Acids Res., 30, e28.
Frigola J, Sole X, Paz MF, Moreno V, Esteller M, Capella G and Peinado MA . (2005). Hum. Mol. Genet., 14, 319–326.
Ghoshal K, Datta J, Majumder S, Bai S, Dong X, Parthun M and Jacob ST . (2002). Mol. Cell. Biol., 22, 8302–8319.
Grunau C, Clark SJ and Rosenthal A . (2001). Nucleic Acids Res., 29, e65.
Gupta RA, Wang D, Katkuri S, Wang H, Dey SK and DuBois RN . (2004). Nat. Med., 10, 245–247.
Hatae T, Wada M, Yokoyama C, Shimonishi M and Tanabe T . (2001). J. Biol. Chem., 276, 46260–46267.
Jones PA and Baylin SB . (2002). Nat. Rev. Genet., 3, 415–428.
Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Malkinson AM, Golpon HA, Nemenoff RA and Geraci MW . (2002). Cancer Res., 62, 734–740.
Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, Nemenoff RA, March TH, Nana-Sinkam SP and Geraci MW . (2004). Cancer Res., 64, 5897–5904.
Lim H and Dey SK . (2002). Endocrinology, 143, 3207–3210.
Paz MF, Wei S, Cigudosa JC, Rodriguez-Perales S, Peinado MA, Huang TH and Esteller M . (2003). Hum. Mol. Genet., 12, 2209–2219.
Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K and Nukiwa T . (2002). Cancer Res., 62, 63–66.
Risques RA, Moreno V, Marcuello E, Petriz J, Cancelas JA, Sancho FJ, Torregrosa A, Capella G and Peinado MA . (2001). Lab. Invest., 81, 307–315.
Sadikovic B, Haines TR, Butcher DT and Rodenhiser DI . (2004). Breast Cancer Res., 6, 30.
Tortola S, Marcuello E, Gonzalez I, Reyes G, Arribas R, Aiza G, Sancho FJ, Peinado MA and Capella G . (1999). J. Clin. Oncol., 17, 1375–1381.
Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG and Davidson NE . (2001). Cancer Res., 61, 7025–7029.
Yokoyama C, Yabuki T, Inoue H, Tone Y, Hara S, Hatae T, Nagata M, Takahashi EI and Tanabe T . (1996). Genomics, 36, 296–304.
Acknowledgements
We thank Gemma Aiza for excellent technical help and Jenny Song and Clare Stirzaker for the 5Aza and TSA treatment of the cells. Grant support: Ministerio de Educación y Ciencia (SAF2003/5821, SAF2004/07579), Fondo de Investigaciones Sanitarias (FIS PI030114), Network of Cooperative Research on Cancer (C03/10) and Epidemiology and Public Health (C03/09), and NH&MRC (293810). JF was the recipient of a fellowship from the Ministry of Education and Science at the Universitat Autònoma de Barcelona.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Frigola, J., Muñoz, M., Clark, S. et al. Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy. Oncogene 24, 7320–7326 (2005). https://doi.org/10.1038/sj.onc.1208883
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208883
Keywords
This article is cited by
-
Hypoxia-hindered methylation of PTGIS in endometrial stromal cells accelerates endometriosis progression by inducing CD16− NK-cell differentiation
Experimental & Molecular Medicine (2022)
-
Alternative activation of macrophages by prostacyclin synthase ameliorates alcohol induced liver injury
Laboratory Investigation (2021)
-
CIRBP is a novel oncogene in human bladder cancer inducing expression of HIF-1α
Cell Death & Disease (2018)
-
Genome-wide analysis of DNA methylation and gene expression defines molecular characteristics of Crohn’s disease-associated fibrosis
Clinical Epigenetics (2016)
-
Overexpression of PTGIS Could Predict Liver Metastasis and is Correlated with Poor Prognosis in Colon Cancer Patients
Pathology & Oncology Research (2012)